PMID- 10659442
OWN - NLM
STAT- MEDLINE
DCOM- 20000411
LR  - 20161116
IS  - 0368-2781 (Print)
IS  - 0368-2781 (Linking)
VI  - 52
IP  - 11
DP  - 1999 Nov
TI  - [Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its 
      efficacy according to breakpoint].
PG  - 661-6
AB  - The levels of levofloxacin (LVFX) in the serum, sputum and lung tissue were 
      measured by a high-performance liquid chromatography method, and the penetration 
      ratio of LVFX into respiratory tissue was investigated. The subjects of this 
      study were 23 patients under pulmonectomy or brochoscopy. LVFX at the dose of 200 
      mg was given orally and specimens were collected as follows; serum at 2, 3 and 5 
      hours after, sputum at 2 hours after, and lung tissue at 3 and 5 hours after the 
      administration, respectively. The mean level of LVFX in lung tissue at 3 hours 
      was 3.91 +/- 2.33 micrograms/g, and those in sputum and in serum at 2 hours were 
      0.71 +/- 0.63 and 2.08 +/- 1.01 micrograms/ml, respectively. A very strong 
      correlation was demonstrated between the level of LVFX in lung tissue and that in 
      serum (p < 0.0001), but correlation between those in sputum and in serum was not 
      significant. The penetration ratio of LVFX into lung tissue was 217.2% and that 
      into sputum was 4.05%. Based on the results of this study, the breakpoints (BPs) 
      of LVFX for pneumonia and chronic respiratory tract infections were calculated to 
      be 4 micrograms/ml and 1 microgram/ml, respectively. It was concluded that 
      penetration of LVFX into lung tissue was satisfactory, and the tissue level of 
      LVFX exceeded greatly the MIC90s against the typical pathogenic bacteria of 
      respiratory tract infections. Taking the excellent BP for pneumonia, 4 
      micrograms/ml, into consideration, it was thought that LVFX is an effective 
      antibacterial agent against pneumonia and other respiratory tract infections.
FAU - Fujita, A
AU  - Fujita A
AD  - Department of Surgery II, Kyorin University School of Medicine, Tokyo, Japan.
FAU - Miya, T
AU  - Miya T
FAU - Tanaka, R
AU  - Tanaka R
FAU - Hirayama, S
AU  - Hirayama S
FAU - Isaka, H
AU  - Isaka H
FAU - Ono, Y
AU  - Ono Y
FAU - Koshiishi, Y
AU  - Koshiishi Y
FAU - Goya, T
AU  - Goya T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Jpn J Antibiot
JT  - The Japanese journal of antibiotics
JID - 0154402
RN  - 6GNT3Y5LMF (Levofloxacin)
RN  - A4P49JAZ9H (Ofloxacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - *Levofloxacin
MH  - Lung/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Ofloxacin/blood/*pharmacokinetics/therapeutic use
MH  - Pneumonia/drug therapy/metabolism
MH  - Respiratory Tract Infections/drug therapy/metabolism
MH  - Saliva/chemistry
MH  - Time Factors
EDAT- 2000/02/05 09:00
MHDA- 2000/04/15 09:00
CRDT- 2000/02/05 09:00
PHST- 2000/02/05 09:00 [pubmed]
PHST- 2000/04/15 09:00 [medline]
PHST- 2000/02/05 09:00 [entrez]
PST - ppublish
SO  - Jpn J Antibiot. 1999 Nov;52(11):661-6.